Sterile Injectable Product And CMO Volume

By Industry Standard Research

ISR asked respondents responsible for sterile injectable manufacturing outsourcing about the numbers and types of outsourced compounds they have in development and in marketing or foresee themselves having in five years. Overall, respondents anticipate having one additional small molecule sterile injectable product on the market within the next five years. Rates were on par for marketed biologic products, which are also predicted to increase by one product over the next five years.